Get the Stockscreener App
84.32
3.09%
-2.69
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $84.32, with a volume of 10.89M.
It is down -3.09% in the last 24 hours and down -18.58% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$87.01
Open:
$87.155
24h Volume:
10.89M
Relative Volume:
0.93
Market Cap:
$146.87B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
23.49
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-5.75%
1M Performance:
-18.58%
6M Performance:
-33.27%
1Y Performance:
-37.07%
1-Day Range:
$84.08
$87.31
1-Week Range:
$84.08
$89.72
52-Week Range:
$84.08
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
84.32 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
285.47 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
76.15 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.93 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
79.96 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress - The Motley Fool
Abbott Laboratories Hires PhronesisDC on Tax Policy - Legis1
Abbott Laboratories Is On Sale, Don't Overlook It - Seeking Alpha
Abbott Laboratories: Mispriced Growth Behind Near-Term Noise? - TradingView
Abbott Laboratories stock (US0028241000): Shares hit 52-week low amid sector weakness and valuation - AD HOC NEWS
Abbott ends six-session losing streak - MSN
Pay Less, Gain More: RMD, MDT Top Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock (ABT) Closed Down by 3.22% on May 8: A Full Analysis - TradingKey
Abbott’s BurstDR Trial Targets Painful Diabetic Neuropathy: What Investors Should Watch - TipRanks
Abbott Laboratories stock hits 52-week low at $86.15 By Investing.com - Investing.com Canada
Abbott Laboratories stock hits 52-week low at $86.15 - Investing.com
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook - Yahoo Finance
Abbott Laboratories Stock: Analyst Estimates & Ratings - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Presents a Decent Value Opportunity After 21% Pullback - ChartMill
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
Medtronic or Abbott Laboratories: Which Stock Has More Upside? - Trefis
Between Medtronic and Abbott Laboratories, Which Stock Looks Set to Break Out? - Trefis
Immunoassay Market Competitive Analysis to 2031 | Abbott, - openPR.com
Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness? - Yahoo Finance
What Abbott Laboratories (ABT)'s New AI Cardiac Imaging, Trial Data and Share Plan Mean For Shareholders - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Abbott ends six-session losing streak (ABT:NYSE) - Seeking Alpha
Abbott Cardiac Data Sheds Light On Heart Rhythm Pipeline And Earnings Story - Yahoo Finance
Abbott loses appeal of nearly $500 million infant formula verdict - Crain's Chicago Business
Assessing Abbott Laboratories (ABT) Valuation After Prolonged Share Price Weakness - simplywall.st
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $109 - Moomoo
Abbott stock is trading at 52-week lows but insiders are gobbling up shares of this blue-chip dividend payer - MSN
Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula - Chicago Tribune
Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer - Barchart.com
Missouri appeals court upholds $495M ruling against Abbott in baby formula case - Seeking Alpha
Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook - Traders Union
Bioabsorbable Stents Industry Projected to Grow at 10.2% CAGR, - openPR.com
Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase - marketscreener.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott gets FDA nod, CE mark for AI-enabled imaging device - MedTech Dive
Abbott Laboratories: performance and outlook - Business Recorder
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Offers Growth Potential and High Dividends - HarianBasis.co
Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co - MarketBeat
ABT: Abbott Laboratories Director Acquires 10,000 Shares Amid De - GuruFocus
AGNC, Lam, Abbott, BlackRock, Schlumberger: Insider Shockwave - TipRanks
Strs Ohio Decreases Stake in Abbott Laboratories $ABT - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
Abbott Laboratories: Attractive Dividend Investment Opportunity - Intellectia AI
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
3.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):